The phase 3 RCT of oral semaglutide add-on therapy evaluating the efficacy and safety of oral semaglutide in T2D subjects with moderate renal impairment (PIONEER-5) 49 demonstrated significantly greater HbA1c improvement compared with placebo of 0.8% and weight reduction of 2.5 kg
There are also non-approved variations like oral semaglutide drops , sublingual semaglutide tablets , semaglutide lozenges , and even semaglutide gummies marketed by compounding pharmacies or online sellers
Diabetes medications: insulin, pioglitazone (Actos), glipizide (Glucotrol), etc
The SYNCHRONIZE-1 trial reported 16.6% mean body weight reduction at 76 weeks
The improvement occurred regardless of different background characteristics and testicular function, suggesting that the benefits are broadly applicable rather than limited to specific patient subsets
By Amanda Frost, PhD Vice President, Research, PCMA There is no shortage of opinions these days about GLP-1 prescription drugs: touting benefits for patients